President Donald Trump proposed a 100% import tariff on generic drugs to encourage pharmaceutical companies to move production to the U.S. [1].
The plan seeks to reduce American reliance on foreign suppliers, such as India, by making overseas production cost-prohibitive. If implemented, the policy would force global manufacturers to choose between paying steep levies or building factories within U.S. borders.
Under the proposal, the tariffs are scheduled to take effect in August 2028 [3]. This timeline provides manufacturers with a two-year grace period to relocate their production facilities to the United States [2].
The initial tariff rate is set at 100% [1]. However, some reports indicate the costs could escalate further, with the tariff potentially rising to 200% in 2029 [4].
Industry players are already reacting to the prospect of these trade barriers. Sandoz, a major generic drug maker, said it would engage with the U.S. government regarding the plan [2].
The administration's strategy focuses on the reshoring of low-cost drug production to secure the domestic supply chain [1], [5]. By targeting generic medications, which make up a vast majority of prescriptions filled in the U.S., the policy targets the most price-sensitive sector of the healthcare market.
“President Donald Trump proposed a 100% import tariff on generic drugs”
This policy represents a significant shift toward pharmaceutical protectionism. While the two-year window is intended to prevent immediate drug shortages, the transition of complex chemical manufacturing to the U.S. is a multi-year process. If companies cannot reshore quickly enough, the 100% tariff may lead to substantial price increases for generic medications, potentially offsetting the cost savings typically associated with non-brand drugs.
